Colostrinin
Also known as: PRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptide
Colostrinin is a research compound. Not approved as a drug for Alzheimer's treatment.
Overview
Proline-rich polypeptide complex isolated from ovine (sheep) colostrum. Originally researched as an Alzheimer's disease modulator, colostrinin has shown ability to stabilize cognitive function and reduce progression in mild-to-moderate Alzheimer's patients in double-blind trials. Also studied for immune modulation and anti-aging properties via cytokine balance normalization.
Research Summary
Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.
Dosing Range
low
100mcg
moderate
200mcg
high
400mcg
Units: mcg · Frequency: sublingual, on a 3 days on / 3 days off cycle
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Supplied as sublingual tablets in clinical formulations. Solution form: dissolve in sterile water for injection. The cyclic dosing schedule (3 on/3 off) is recommended in published protocols to prevent receptor downregulation.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Generally well-tolerated
- Mild GI discomfort
- Rare hypersensitivity (relevant for dairy protein sensitivity)
- Mild fatigue (initial days)
Research Papers
2 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Community discussion on colostrinin for Alzheimer's prevention and cognitive aging, with notes on sourcing.
View original threadLongevity researcher discussion on proline-rich polypeptides from colostrum for immune and cognitive aging.
View original threadOverview
Colostrinin (also designated PRP — proline-rich polypeptide) is a complex of low-molecular-weight proline-rich peptides extracted from ovine colostrum — the first milk produced by sheep after delivery. Colostrum is well-known for its dense concentration of immune factors, antibodies, growth factors, and bioactive peptides, but colostrinin represents a specific characterized fraction.
The compound attracted research attention in the 1990s and 2000s primarily through Polish researchers at the Ludwik Hirszfeld Institute of Immunology who identified its immunomodulatory properties and subsequently investigated its potential in Alzheimer's disease — a condition with significant neuroinflammatory components.
Mechanism
Immune Modulation
Colostrinin's most established mechanism involves dendritic cell (DC) and lymphocyte signaling:
- Th1/Th2 cytokine balance: Shifts immune tone toward Th2 anti-inflammatory dominance
- Reduces: IL-6, IL-12, TNF-α (pro-inflammatory)
- Increases: IL-10 (anti-inflammatory, regulatory)
- Dendritic cell maturation: Modulates DC phenotype, affecting downstream adaptive immune responses
- Reactive oxygen species: Reduces oxidative stress markers in immune cells and neural tissue
Neuroprotective Mechanisms
In neurological research context:
Amyloid-β Aggregation Inhibition Colostrinin peptides directly interfere with Aβ oligomerization and fibril formation in vitro:
- Binds Aβ1-42 monomer, reducing its stacking into toxic oligomers
- Reduces Aβ-induced neurotoxicity in neural cell culture models
NGF Upregulation
- Increases nerve growth factor expression in brain tissue
- Supports cholinergic neuron maintenance (the primary degeneration target in AD)
HPA Axis Modulation
- Reduces excess cortisol (elevated in AD and cognitive aging)
- Normalizes HPA axis hyperactivity that contributes to hippocampal atrophy
Oxidative Stress Reduction
- Reduces lipid peroxidation products in neuronal membranes
- Upregulates SOD and catalase activity
Why the Cyclic Dosing Schedule?
The recommended 3 days on / 3 days off protocol is based on receptor dynamics. Continuous stimulation of certain receptor systems can lead to desensitization. The alternating schedule:
- Allows receptor recovery during off days
- Maintains sensitivity to colostrinin's active components
- Reduces total dose without sacrificing efficacy
Clinical Trial Data
The primary Alzheimer's trial (Leszek et al., 2002):
- 46 patients, mild-to-moderate AD
- Double-blind, placebo-controlled, 15 weeks
- Colostrinin group: statistically significant reduction in cognitive decline (MMSE, CDR scales)
- Placebo group: continued cognitive deterioration
- Effect classified as "stabilization" — not reversal, but halting of progressive decline
A subsequent larger trial showed more mixed results, which has limited adoption in Western clinical practice. The compound remains in research status.
Related Nootropic Peptides
Cerebrolysin
NootropicFPF 1070 · EBEWE Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Un…
Cortexin
Nootropiccortexin polypeptide · cortexin-10
Polypeptide nootropic extracted from the cortex of cattle or pigs, containing a mixture of low-molecular-weight neuropep…
Dihexa
NootropicPNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is a synthetic hexapeptide derived from angiotensin IV, developed at Washington State University. It is considere…